Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

• Status: Unknown status
• Trial end date: 2016-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety for the combination of Rivaroxaban and Ticagrel versus triple antithrombotic regimen (Vitamin K Antagonist (VKA), Clopigogrel and Aspirin) in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention (PCI).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Anzhen Hospital
• Treatments: Clopidogrel; Rivaroxaban; Warfarin

Criteria

Inclusion Criteria:

• a long-term indication for oral anticoagulation treatment (until at least 1 year after the study)

• a severe coronary lesion (at least 75% stenosis on angiography or fractional flow reserve lower than 0•80) with indication for PCI

• age 18-80 years

Exclusion Criteria:

• history of intracranial bleeding;

• cardiogenic shock;

• contra indication to use of antiplatelet or anticoagulation drugs;

• peptic ulcer in the previous 6 months;

• thrombo cytopenia (platelet concentration lower than 50~10⁹/L);

• major bleeding (according to the Thrombolysis in Myocardial Infarction [TIMI] criteria) in the past 12 months; and

• pregnancy.